In related news, CFO Robin L. Washington sold 51,820 shares of Gilead Sciences in a transaction that occurred on Thursday, September 7. The stock was sold at an average price of $ 85.00, for a total transaction of $ 4,404,700.00. After the transaction, the CFO now holds 43.352 shares in the company, valued at $ 3,684,920. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. In addition, EVP Gregg H. Alton sold 25,000 shares of Gilead Sciences in a transaction that took place on Monday, October 2. The stock was sold at an average price of $ 82.65, for a total value of $ 2,066,250.00. The disclosure of this sale can be found here. In the last quarter, the initiates have sold 546,819 shares of the company's stock for a value of $ 41,808,839. 1.30% of the shares are currently owned by company experts.
Shares of Gilead Sciences, Inc. (NASDAQ: GILD) remained stable at $$ 73.29 during business hours on Wednesday. The company had a trading volume of 6,077,088 shares, compared to its average volume of 9,215,701. The company has a debt-to-equity ratio of 1.10, a current ratio of 3.68 and a fast ratio of 3.56. The stock has a market capitalization of $ 95,475.20, a price-earnings ratio of 7.63, a price-profit-growth ratio of -1.22 and a beta of 1.13. Gilead Sciences, Inc. has a minimum of 52 weeks of $ 63.76 and a maximum of 52 weeks of $ 86.27.
Gilead Sciences (NASDAQ: GILD) last issued its quarterly earnings results on Thursday, October 26. The biopharmaceutical company reported $ 2.27 of earnings per share (EPS) for the quarter, beating Zacks' consensus estimate of $ 2.13 for $ 0.14. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The company had revenues of $ 6.51 billion for the quarter, compared to analysts' estimates of $ 6.40 billion. During the same period of the previous year, the company recorded earnings per share of $ 2.75. The company's income decreased 13.2% year-on-year. Research analysts predict that Gilead Sciences, Inc. will record 8.53 earnings per share for the current year.
The business also recently revealed a quarterly dividend, which will be paid on Thursday, December 28. Investors registered on Friday, December 15 will receive a dividend of $ 0.52 per share. The ex-dividend date is Thursday, December 14th. This represents a dividend of $ 2.08 annualized and a yield of 2.84%. The payment index of Gilead Sciences is 23.69%.
Several research firms have commented on GILD. BidaskClub reduced Gilead Sciences from a "buy" rating to a "suspense" rating in a research note on Wednesday, August 9. Mizuho reiterated a "buy" rating on Gilead Sciences shares in a research note on Friday, September 29. Maxim Group reiterated a "suspension" rating on Gilead Sciences shares in a research note on Thursday, October 19. Berenberg Bank restated a "buy" rating and issued a price target of $ 86.00 (up to $ 79.00) on Gilead Sciences shares in a research note on Sunday, August 20. Finally, Cowen reiterated a "superior performance" rating and issued a price target of $ 90.00 on shares of Gilead Sciences in a research note on Thursday, August 31. One analyst has rated the stock with a sales rating, eleven have granted a withholding grade, nineteen have granted a purchase rating and one has assigned a strong purchase rating to the stock. Currently, the stock has an average "Buy" rating and a consensus target price of $ 85.22.
ILLEGAL ACTIVITY NOTICE: "The Associated Banc Corp holds a position of $ 5.13 million in Gilead Sciences, Inc. (GILD)" according to The Ledger Gazette. and is the exclusive property of The Ledger Gazette. If you are viewing this piece in another domain, it was illegally copied and republished in violation of the United States and international copyright and trademark law. The correct version of this piece can be accessed at https://ledgergazette.com/2017/12/07/associated-banc-corp-has-5-13-million-stake-in-gilead-sciences-inc-gild . html
Gilead Sciences Profile
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and markets drugs in areas of unmet medical need. The Company's portfolio of products and the research portfolio includes treatments for the Human Immunodeficiency Virus / Acquired Immunodeficiency Syndrome (HIV / AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular diseases.
Get news and ratings from Gilead Sciences Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and companies related to the FREE Daily Bulletin of MarketBeat.com.